PMID- 17605871
OWN - NLM
STAT- MEDLINE
DCOM- 20091211
LR  - 20161018
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 15
IP  - 3
DP  - 2007 Jun
TI  - [Enhancing effect of dendritic cells derived from human cord blood on T cells in 
      killing tumor cells].
PG  - 586-90
AB  - Dendritic cells (DCs) derived from bone marrow cells are specialized cells for 
      the uptake, processing, and presentation of foreign and self-antigens. The study 
      indicated that re-transfusion of DCs pulsed with tumor-associated antigen can 
      induce an vigorous specific anti-tumor response in clinic. The present study was 
      aimed to investigate the enhancing effect of DCs derived from human cord blood on 
      T cells in killing tumor cells. Human cord blood mononuclear cells were isolated 
      from human cord blood by density gradient centrifugation using lymphocyte 
      separating medium, and cord blood mononuclear cells were obtained by adherence 
      and cultured in a liquid culture system with GM-CSF and IL-4 for 15 days. Then 
      the cells were analyzed for phenotypes of CD1a by indirect immunofluorescence. 
      The capacity of DCs to initiate T cell-dependent anti-tumor immune responses was 
      assayed by MTT kit. The ratios of DCs to tumor cells in experimental groups were 
      20:1, 50:1 and 100:1 respectively. The DCs were not added in control group. The 
      results indicated that in the presence of GM-CSF and IL-4, the DCs with typical 
      morphological features at days 15 were observed. At that time, (43.12 +/- 5.83)% 
      CD1a(+) cells were obtained. In addition to these phenotypic properties, the DC 
      of experimental groups could remarkably initiate T cell-dependent anti-tumor 
      immune responses with different ratios compared with control group (P < 0.01), 
      there were no significant difference of killing effects between 100:1 and 50:1 
      groups (P > 0.05), and killing effect of DC in 20:1 group was higher than that in 
      100:1 or 50:1 groups (P < 0.05). It is concluded that human cord blood 
      mononuclear cells can serve as a better source of DC, which can promote the 
      capacity to initiate T cell-dependent anti-tumor immune responses.
FAU - Qu, Xin-Dong
AU  - Qu XD
AD  - Department of Pediatrics, The Affiliated Hospital of Qingdao University Medical 
      College, Qingdao 266003, China.
FAU - Qu, Zheng-Hai
AU  - Qu ZH
FAU - Zuo, Jian-Xin
AU  - Zuo JX
FAU - Sun, Li-Rong
AU  - Sun LR
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - 0 (Recombinant Proteins)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Apoptosis/*immunology
MH  - Brain Neoplasms/pathology
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/*immunology
MH  - Fetal Blood/*cytology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Interleukin-4/pharmacology
MH  - Leukocytes, Mononuclear/cytology
MH  - Neuroblastoma/*pathology
MH  - Recombinant Proteins
MH  - T-Lymphocytes/*immunology
MH  - Tumor Cells, Cultured
EDAT- 2007/07/04 09:00
MHDA- 2009/12/16 06:00
CRDT- 2007/07/04 09:00
PHST- 2007/07/04 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
PHST- 2007/07/04 09:00 [entrez]
AID - 1009-2137(2007)03-0586-05 [pii]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Jun;15(3):586-90.